Table of Contents
Of every dollar a biotech spends bringing a cell or gene therapy to market, a large share goes to the contract research organisation running the trial. Choose the wrong CRO and the programme stalls before it reaches patients.
Most CROs were built for small-molecule oncology, not for therapies that have to be manufactured fresh per patient and shipped under tight cold-chain windows.
CTI Clinical Trial and Consulting Services is one of a small group of CROs purpose-built for the operational complexity of advanced therapies, with deep franchises in regenerative medicine and gene therapy, rare disease, transplantation and paediatric studies. Founded in 1999 and now operating across North America, Europe, Latin America, the Middle East, Africa and Asia-Pacific, CTI has supported sponsors from preclinical strategy through commercialisation – a profile that matters as more cell therapy programmes move from single-site academic studies into globally registered trials.
At Meeting on the Med 2026, reporting for Onyx, Federico Citterich sat down with Josh Schroeder to find out more.
A special thanks to our Onyx Live sponsors:
Cellares - delivering cell therapy manufacturing excellence at scale across a global network of IDMO smart factories https://www.cellares.com/
Comments